Best vancomycin dosing software: free two-level equations vs Bayesian platforms compared

The 2020 consensus guideline moved vancomycin monitoring from trough targets to AUC targets, and in doing so it created a purchasing decision that most pharmacy departments had never had to make. Someone now has to decide whether AUC gets calculated by a pharmacist with two levels and a spreadsheet, or by software the health system pays for every year.

This is a comparison of what is actually on the market, what each option is verified to cost, and the question that should decide it. Every price claim here was checked at the vendor's own material in August 2026. Where a vendor publishes nothing, this guide says so instead of repeating a figure from a review site.

The short answer

If your patients are stable and at steady state, you do not need to buy anything: the two-level first-order method is free, it is graded A-II in the same guideline that grades Bayesian software A-II, and ClinCalc runs it at no cost. Buy Bayesian software when a meaningful share of your vancomycin patients are unstable, because that is the case first-order equations cannot handle. Bayesian tools work from one or two levels and do not require steady state, and that single capability, not accuracy on an easy patient, is what you are paying for. Of the 12 Bayesian programs identified in the published literature, only ClinCalc and VancoCalc are free; every other one carries a subscription fee, and essentially none of them publish it.

What is actually on the market

A 2022 review in the pharmacy literature enumerated the field rather than sampling it, naming 12 software programs that use Bayesian estimation for vancomycin therapeutic monitoring in adults: Adult and Pediatric Kinetics, Best Dose, ClinCalc, DoseMeRx, ID-ODS, InsightRx, MwPharm++, NextDose, PrecisePK, TDMx, Tucuxi and VancoCalc. Its finding on cost is one sentence and worth quoting: both ClinCalc and VancoCalc are free online dosing software while all others require subscription fees.

The pattern in that price column will look familiar to anyone who has bought clinical content before. It is the same asymmetry that runs through drug references: the products aimed at individual clinicians publish a number, and the products sold to health systems publish nothing. Wolters Kluwer is the clearest illustration, because the same company publishes $29.99 a month for Lexidrug and nothing at all for Sentri7 Bayesian dosing. That tracks who signs the check, not product quality.

The question that should decide it

Most evaluations start by comparing accuracy, which is the wrong end of the problem, because on a stable patient at steady state the two approaches largely agree. Start instead with a census question: what fraction of your vancomycin patients are actually at steady state when the levels come back?

In a general medical floor population the answer is usually most of them, and free first-order arithmetic covers the work. In an ICU, a burn unit, a trauma service, or anywhere with a lot of augmented renal clearance and rapidly moving creatinine, the answer can be a minority, and every one of those patients is a case where two-level equations quietly describe a patient who no longer exists. Bayesian estimation handles them because it starts from a population prior rather than from an assumption of steady state. If your census is the first kind, software is a convenience. If it is the second, it is doing something you genuinely cannot do by hand.

The second question is where the AUC has to appear. A number a pharmacist calculates in a browser and types into a note is a different product from a number that lands in the EHR beside the order, and the integration is usually where most of the cost and nearly all of the implementation time goes.

How much does vancomycin Bayesian software cost?

No major vendor publishes a list price. DoseMeRx, InsightRx, PrecisePK and Sentri7 are all sold by quote, and the figure depends on the depth of EHR integration, the size of the institution, how many drugs beyond vancomycin are covered, and the contracting relationship you already have. That means the only honest budget number is the one you get in writing from the vendor for your own site, and it also means any per-bed figure you find quoted on a software review site should be treated as unverified.

What you can price accurately is the alternative. Free first-order calculation costs pharmacist time plus one extra level per assessment, and both of those are numbers your own department already knows.

Do you need software to calculate vancomycin AUC?

No. The guideline is explicit that AUC can be accurately estimated from two timed steady-state concentrations using first-order pharmacokinetic equations, and it grades that recommendation A-II, the same grade it gives Bayesian software. The arithmetic is a natural log, two exponentials and two trapezoids. Our vancomycin calculator runs exactly those equations in the browser and shows every intermediate value, including a clearance cross-check that catches mistimed draws before they reach a note.

What software buys is not a different answer on an easy patient. It is coverage of the hard ones, plus consistency across a rotating staff, plus an audit trail.

The hidden cost nobody budgets for

Every department that switches to AUC monitoring discovers the same thing about six weeks in: the binding constraint is not the calculation, it is the draw. Two timed levels only work if the times are real, and getting reliably documented draw times out of a busy floor is a nursing workflow change, not a pharmacy one. Bayesian software reduces how many levels you need but does not remove this problem, because a mistimed level degrades a Bayesian estimate too.

Budget for the training, and for a way to confirm it landed. Health systems running a change of this kind across several units often pair the rollout with a structured read on how ready each department actually is, and a departmental readiness and process maturity assessment is a more reliable signal than asking managers whether their teams are comfortable with the new protocol. The units that report confidence and the units that document draw times correctly are frequently not the same units.

The other thing worth planning for is what happens to the spreadsheets. Most departments have at least one vancomycin workbook in circulation, usually written by a resident who has since left. When the protocol changes, uncontrolled copies keep running the old one. Either retire them deliberately or give them an owner and a review date.

Is ClinCalc good enough for a hospital?

For the arithmetic, yes. ClinCalc implements documented Bayesian modeling and the Sawchuk-Zaske method, it is free, and the author has stated the site will remain free. Many residency programs teach on it.

The objection is not accuracy, it is institutional. ClinCalc is maintained by an individual pharmacist author, which means no vendor contract, no service level commitment, no support path when it is down at 2am, and no one to answer a security review. For a pharmacist checking their own work that is irrelevant. For a tool written into a system-wide protocol that a joint commission surveyor may ask about, it is the whole conversation. Departments regularly resolve this by permitting ClinCalc for individual use while requiring the protocol itself to name a method rather than a website.

What about the renal function estimate underneath it?

Vancomycin is renally cleared, so every one of these tools rests on a kidney function estimate, and that estimate is in the middle of a national transition. A 2025 National Kidney Foundation workgroup consensus in the American Journal of Health-System Pharmacy recommends that health systems, laboratories, EHR vendors and compendia move away from Cockcroft-Gault estimated creatinine clearance toward the race-free 2021 CKD-EPI equation for medication decisions, individualized to body surface area.

In practice most legacy labeling still states thresholds in creatinine clearance while your chemistry panel reports indexed eGFR, so US pharmacists currently work with both and have to keep the units straight. The creatinine clearance calculator covers that side, including the body weight choice that moves the answer more than the choice of software does. We also compared the broader field of drug dosing calculator apps for pharmacists, where the same publish-nothing pattern shows up across drug references.

Frequently asked questions

What is the best vancomycin dosing software?

There is no single best. For departments whose vancomycin patients are mostly stable, the free two-level first-order method covers the work and ClinCalc runs it at no cost. For ICU-heavy populations with unstable renal function, a Bayesian platform with EHR integration such as DoseMeRx, InsightRx, PrecisePK or Sentri7 is doing something first-order equations cannot. Choose on your patient census, not on a feature list.

Is vancomycin AUC dosing required?

The 2020 ASHP, IDSA, PIDS and SIDP consensus guideline recommends AUC-guided dosing and monitoring for serious MRSA infection and explicitly withdrew the previous trough-only target of 15 to 20 mg/L. It is a guideline recommendation rather than a regulation, so what is required at your site is whatever your institutional protocol says. Most US health systems have moved or are moving.

How many vancomycin levels does AUC dosing need?

Two timed steady-state levels for the first-order method, drawn in the same interval, typically a postdistributional peak 1 to 2 hours after the infusion ends and a trough. Bayesian software can work from one or two, and does not require steady state, though the guideline notes two samples remain preferable.

Does Epic have vancomycin AUC dosing built in?

Not as a Bayesian engine of its own. Health systems generally reach AUC-guided dosing inside Epic by integrating a third-party Bayesian platform, which is why integration depth is usually the largest line in the quote. Confirm what your specific build supports with your own informatics team rather than assuming it from a vendor claim.

Can you calculate vancomycin AUC without software?

Yes, with two timed levels and first-order equations, which is the method the guideline grades A-II. Calculate the elimination rate constant from the two concentrations and the hours between them, extrapolate the true peak and trough, then combine a linear trapezoid across the infusion with a log-linear trapezoid across the elimination phase and scale to 24 hours.

Where this leaves the decision

Run the census first. Count what share of your vancomycin patients are genuinely at steady state when levels return, and you will usually find the decision has already made itself. A stable population does not need a purchase order, it needs a written method and consistent draw times. An unstable one needs software, and the vendor conversation should start with integration and support rather than with accuracy claims, because on the patients that matter the accuracy argument is really an argument about steady state.

Whichever way it goes, the exposure calculation is only half the check. An AUC in range says nothing about the piperacillin-tazobactam, the loop diuretic or the contrast study sitting further down the same medication list, and that screen belongs beside the arithmetic rather than after it.